$TLSI
TriSalus Life Sciences Inc Stock $tlsi

$tlsi Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000182666723000007 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$5.721M	$5.193M	$0.00
YoY Change
Cost Of Revenue	$582.0K	$589.0K
YoY Change		-15.98%
Gross Profit	$5.139M	$4.604M
YoY Change		42.89%
Gross Profit Margin	89.83%	88.66%
Selling, General & Admin	$11.62M	$13.71M	$1.356M
YoY Change	756.9%	3072.85%	18.77%
% of Gross Profit	226.08%	297.87%
Research & Development	$7.639M	$9.367M
YoY Change		94.82%
% of Gross Profit	148.65%	203.45%
Depreciation & Amortization	$202.0K	$166.0K
YoY Change
% of Gross Profit	3.93%	3.61%
Operating Expenses	$19.26M	$23.08M	$1.356M
YoY Change	1320.32%	5239.98%	18.77%
Operating Profit	-$14.12M	-$18.48M
YoY Change		4174.86%
Interest Expense	$59.00K	$4.000K	$1.629M
YoY Change	-96.38%	-99.61%	20470.45%
% of Operating Profit
Other Income/Expense, Net	-$21.45M	-$13.00K	-$265.3K
YoY Change	7983.9%	-101.01%	-106.58%
Pretax Income	-$35.51M	-$1.286M	$8.030K
YoY Change	-442291.78%	-251.16%	-99.72%
Income Tax	$1.000K	$0.00	$351.4K
% Of Pretax Income			4375.72%
Net Earnings	-$36.31M	-$1.286M	-$343.3K
YoY Change	10475.23%	-295.01%	-111.86%
Net Earnings / Revenue	-634.66%	-24.76%
Basic Earnings Per Share		-$0.13
Diluted Earnings Per Share	-$0.81	-$0.13	-$0.01
COMMON SHARES
Basic Shares Outstanding	26.32M shares	13.17M shares
Diluted Shares Outstanding		13.17M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.78M	$21.38M	$153.6K
YoY Change	7569.31%	10200.1%	-23.56%
Cash & Equivalents	$11.78M	$21.38M	$153.6K
Short-Term Investments
Other Short-Term Assets	$5.972M	$2.977M	$206.3K
YoY Change	2794.39%	2918.35%	-36.51%
Inventory	$2.545M	$1.629M	$1.471M
Prepaid Expenses	$2.986M	$2.977M	$206.3K
Receivables	$3.554M	$3.052M	$1.557M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$20.86M	$29.04M	$359.9K
YoY Change	5696.74%	9383.61%	-31.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.270M	$1.897M	$2.231M
YoY Change	46.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$466.0K	$367.0K	$19.83M
YoY Change	-97.65%	-99.85%	-92.07%
Total Long-Term Assets	$4.863M	$4.513M	$19.83M
YoY Change	-75.47%	-98.2%	-92.07%
TOTAL ASSETS
Total Short-Term Assets	$20.86M	$29.04M	$359.9K
Total Long-Term Assets	$4.863M	$4.513M	$19.83M
Total Assets	$25.73M	$33.55M	$20.19M
YoY Change	27.43%	-86.65%	-91.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.391M	$1.899M	$1.443M
YoY Change	135.01%	135.53%	36.43%
Accrued Expenses	$10.88M	$6.600M	$6.377M
YoY Change	70.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.69M	$9.305M	$2.502M
YoY Change	487.01%	386.22%	56.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.341M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$36.98M	$15.76M	$9.811M
YoY Change	276.87%	65.12%	-37.3%
Total Long-Term Liabilities	$36.98M	$15.76M	$11.15M
YoY Change	231.55%	53.84%	-28.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.69M	$9.305M	$2.502M
Total Long-Term Liabilities	$36.98M	$15.76M	$11.15M
Total Liabilities	$51.66M	$25.07M	$13.65M
YoY Change	278.36%	106.15%	-20.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$248.4M	-$212.9M	-$13.27M
YoY Change	1772.11%	1725.65%	-20.64%
Common Stock	$2.000K	$2.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$25.94M	$8.487M	-$13.27M
YoY Change
Total Liabilities & Shareholders Equity	$25.73M	$33.55M	$20.19M
YoY Change	27.43%	-86.65%	-91.94%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$36.31M	-$1.286M	-$343.3K
YoY Change	10475.23%	-295.01%	-111.86%
Depreciation, Depletion And Amortization	$202.0K	$166.0K
YoY Change
Cash From Operating Activities	-$8.849M	-$21.46M	-$1.266M
YoY Change	599.14%	6055.37%	85.88%
INVESTING ACTIVITIES
Capital Expenditures	$372.0K	$178.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$328.0K	-$1.139M	$232.8M
YoY Change	-100.14%	-496.86%	387933.57%
Cash From Investing Activities	-$700.0K	-$1.317M	$232.8M
YoY Change	-100.3%	-558.89%	387933.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	43.00K	40.25M	-231.6M
YoY Change	-100.02%	20026.5%	-42675.08%
NET CHANGE
Cash From Operating Activities	-8.849M	-21.46M	-1.266M
Cash From Investing Activities	-700.0K	-1.317M	232.8M
Cash From Financing Activities	43.00K	40.25M	-231.6M
Net Change In Cash	-9.506M	17.48M	-54.02K
YoY Change	17497.19%	12528.42%	-29.77%
FREE CASH FLOW
Cash From Operating Activities	-$8.849M	-$21.46M	-$1.266M
Capital Expenditures	$372.0K	$178.0K
Free Cash Flow	-$9.221M	-$21.63M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	tlsi	Common Stock Share Price Market Price Number Of Consecutive Trading Days CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays	P3D
CY2023Q3	tlsi	Preferred Stock Number Of Trading Days Volume Weighted Average Price PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice	P10D
CY2023Q3	tlsi	Lease Liability Current LeaseLiabilityCurrent	379000	usd
CY2022Q4	tlsi	Lease Liability Current LeaseLiabilityCurrent	370000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	427000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	142000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9305000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32357000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30898162	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26316681	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26316681	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	221351000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10028000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212867000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186358000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8487000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-176330000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33554000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21995000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5193000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3923000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2023000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1442000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	4604000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	3222000	usd
	us-gaap	Gross Profit GrossProfit	10767000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9367000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15091000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3030000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11430000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8881000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9025000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3495000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17498000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8425000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18477000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8111000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40032000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24667000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	116000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	49000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	187000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	75000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	4000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	13000	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q3	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	0	usd
CY2022Q3	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	0	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	-4171000	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	0	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-31000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-56000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-71000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1286000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8093000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23521000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24642000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1286000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-8093000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23529000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24645000	usd
CY2023Q3	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
CY2022Q3	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	2981000	usd
	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	458000	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	458000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1744000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8093000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26968000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24645000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-25.95
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-25.95
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.68
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.68
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-82.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-82.17
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13173422	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13173422	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	311823	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	311823	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4749849	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4749849	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	299936	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	299936	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-176330000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73000	usd
CY2023Q1	us-gaap	Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8268000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-184475000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	69000	usd
CY2023Q2	us-gaap	Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-13974000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-198364000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	259000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	204236000	usd
CY2023Q3	tlsi	Adjustments To Additional Paid In Capital Warrants Assumed In Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization	2568000	usd
CY2023Q3	tlsi	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	957000	usd
CY2023Q3	tlsi	Adjustments To Additional Paid In Capital Recognition Of Derivative Instrument Contingent Consideration Liability AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability	28927000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34151000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1286000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8487000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-129604000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	62000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7873000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-137354000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8679000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-145958000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	119000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-8093000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-153925000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23529000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24645000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	452000	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	-4171000	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	402000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	251000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-60000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-50000	usd
	tlsi	Gain Loss On Milestone Payment For Asset Acquistion GainLossOnMilestonePaymentForAssetAcquistion	-1000000	usd
	tlsi	Gain Loss On Milestone Payment For Asset Acquistion GainLossOnMilestonePaymentForAssetAcquistion	-1000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1477000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	936000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	158000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1041000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1306000	usd
	tlsi	Payments For Assets Acquisition Milestone PaymentsForAssetsAcquisitionMilestone	1000000	usd
	tlsi	Payments For Assets Acquisition Milestone PaymentsForAssetsAcquisitionMilestone	1000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	205000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	63000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1421000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1514000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9189000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3499000	usd
	tlsi	Proceeds From Refundable Prepayments For Preferred Stock ProceedsFromRefundablePrepaymentsForPreferredStock	0	usd
	tlsi	Proceeds From Refundable Prepayments For Preferred Stock ProceedsFromRefundablePrepaymentsForPreferredStock	3986000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9630000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	usd
	tlsi	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	1116000	usd
	tlsi	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	4000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	94000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	73000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54586000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7554000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11969000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17963000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21633000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12338000	usd
	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	25409000	usd
	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2023 (the "Closing Date"), TriSalus Life Sciences, Inc., a Delaware corporation (the “Company,” “TriSalus,” “we,” “us”), formerly known as MedTech Acquisition Corporation (“MTAC”), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November 11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May 13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July 5, 2023 (as amended, the “Merger Agreement”), by and between MTAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (“Merger Sub”) and TriSalus Operating Life Sciences, Inc. (formerly known as TriSalus Life Sciences, Inc.), a Delaware corporation (“Legacy TriSalus”), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and TriSalus Life Sciences, Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as “the Closing.” In connection with the consummation of the Merger, on August 10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences, Inc. to TriSalus Operating Life Sciences, Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences, Inc., the surviving company ("New TriSalus”). As further described in Note 3, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these consolidated financial statements are of Legacy TriSalus.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the Business</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines — Pressure Enabled Drug Delivery (“PEDD™) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with SD-101, is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve™ is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TriNav™ is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (“TPT”) approval from the Centers for Medicare & Medicaid Services (“CMS”), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023. On June 1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications ("APC”) code with CMS and met with CMS on June 26, 2023, to review the application. If granted, the new technology APC code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January 1, 2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement rates, or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SD-101 has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T cells to the tumor, allowing checkpoint inhibitors to work more effectively. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs. In July 2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, and the closing of the Business Combination. Since inception of the Company in 2009 through September 30, 2023, we have issued for cash $164,364 of preferred stock (of which $36,854 was raised at the closing of the Business Combination, including issuance of Series A convertible preferred stock), which, along with </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$551 from common stock and $44,692 from convertible notes and warrants, has funded our accumulated deficit of $212,867. During the nine months ended September 30, 2023, we raised $9,189 in cash through the issuance of Series B-2 preferred stock, $9,630 in cash through the issuance of Series B-3 preferred stock, $94 from the exercise of stock options, and $36,854 from the Business Combination. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had cash and cash equivalents of $21,383. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has an accumulated deficit of $212,867 as of September 30, 2023. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutics company whereby our medical devices will be marketed in combination with the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses — including the development of a candidate pharmaceutical — that, in the short term, will not be fully offset by increased revenues. Without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents will be insufficient to fund our projected liquidity requirements for the next 12 months.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events have raised substantial doubt about our ability to continue as a going concern within one year after the date that these consolidated financial statements were issued. Management’s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management’s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, the process to obtain continuing CMS approval and application for a new ACS code for our PEDD product for reimbursement, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Event</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2023, we entered into a Standby Equity Purchase Agreement (the “Yorkville Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Yorkville Purchase Agreement, the Company shall have the right, but not the obligation, to sell to Yorkville up to $30,000 of common stock, par value $0.0001 per share of the Company (the “Common Stock”), at the Company’s request any time during the commitment period commencing on October 2, 2023 (the “Effective Date”), and terminating on the first day of the month following the 24-month anniversary of the Effective Date. Each issuance </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and sale by the Company to Yorkville under the Yorkville Purchase Agreement (an “Advance”) is subject to a maximum limit equal to the greater of: (i) an amount equal to 100% of the average of the daily volume traded of the Company’s Common Stock on the Nasdaq Stock Market (“Nasdaq”) for the 10 trading days immediately preceding an Advance notice, or (ii) 1,000,000 shares of Common Stock. The shares will be issued and sold to Yorkville at a per-share price equal to, at the election of the Company as specified in the relevant Advance notice: (i) 96% of the Market Price (as defined below) for any period commencing on the receipt of the Advance notice by Yorkville and ending on </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4:00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> p.m. New York City time on the applicable Advance notice date (the “Option 1 Pricing Period”), and (ii) 97% of the Market Price for any <span style="-sec-ix-hidden:f-385">three</span> consecutive trading days commencing on the Advance notice date (the “Option 2 Pricing Period,” and each of the Option 1 Pricing Period and the Option 2 Pricing Period, a “Pricing Period”). “Market Price” is defined as, for any Option 1 Pricing Period, the daily volume-weighted average price (“VWAP”) of the Common Stock on Nasdaq, and for any Option 2 Pricing Period, the lowest VWAP of the Common Stock on the Nasdaq during the Option 2 Pricing Period. The Advances are subject to certain limitations, including that Yorkville cannot purchase any shares that would result in it beneficially owning more than 4.99% of the Company’s outstanding Common Stock at the time of an Advance or acquiring since the Effective Date under the Yorkville Purchase Agreement more than 19.99% of the Company’s outstanding Common Stock, as of the date of the Yorkville Purchase Agreement.</span>
	tlsi	Number Of Product Lines In Development NumberOfProductLinesInDevelopment	2	product_line
	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	551000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212867000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9189000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9630000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	94000	usd
	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21383000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212867000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	tlsi	Standby Equity Purchase Agreement Term StandbyEquityPurchaseAgreementTerm	P24M
CY2023Q3	tlsi	Purchase Agreement Ownership Limitation PurchaseAgreementOwnershipLimitation	0.0499
CY2023Q3	tlsi	Purchase Agreement Exchange Cap PurchaseAgreementExchangeCap	0.1999
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of Credit Risk and Other Risks and UncertaintiesOur cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.
CY2023Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	40150000	usd
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
	tlsi	Preferred Stock Conversion Percentage Of Outstanding Shares PreferredStockConversionPercentageOfOutstandingShares	0.992
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4015002	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q3	tlsi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.02471853	shares
CY2023Q3	tlsi	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	21999886	shares
CY2023Q3	tlsi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.02471853	shares
CY2023Q3	tlsi	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	42854000	usd
CY2023Q3	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	2704000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	40150000	usd
CY2023Q3	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
CY2023Q3	tlsi	Reverse Recapitalization Transaction Costs Incurred ReverseRecapitalizationTransactionCostsIncurred	6069000	usd
CY2023Q3	tlsi	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	1742000	usd
CY2023Q3	tlsi	Reverse Recapitalization Transaction Costs Paid ReverseRecapitalizationTransactionCostsPaid	4327000	usd
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26316681	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2816224	shares
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14266605	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	28927000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	16188000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21383000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9414000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	250000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	250000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21633000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9664000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	250000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	250000	usd
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	289000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	753000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1340000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	718000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1629000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1471000	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	43000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3404000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2905000	usd
CY2023Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2706000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2896000	usd
CY2023Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	475000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	329000	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	15000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	247000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6600000	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	28927000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14266605	shares
	tlsi	Class Of Warrant Or Right Threshold Number Of Days For Warrants To Be Transferable ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable	P30D
CY2023Q3	tlsi	Class Of Warrant Or Right Repurchase Program Authorized Amount ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount	4000000	usd
CY2023Q3	tlsi	Share Based Compensation Arrangement Number Of Plans ShareBasedCompensationArrangementNumberOfPlans	2	plan
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	7500732	shares
CY2023Q3	tlsi	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding	2816224	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4684508	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q3	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	5984998	shares
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	458000	usd
CY2023Q3	tlsi	Preferred Stock Automatic Conversion Period PreferredStockAutomaticConversionPeriod	P4Y
CY2023Q3	tlsi	Preferred Stock Conversion Price Automatic Reset Duration First Reset PreferredStockConversionPriceAutomaticResetDurationFirstReset	P18M
CY2023Q3	tlsi	Preferred Stock Conversion Price Automatic Reset Duration Second Reset PreferredStockConversionPriceAutomaticResetDurationSecondReset	P47M
CY2023Q3	tlsi	Preferred Stock Conversion Price Floor PreferredStockConversionPriceFloor	2.10
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	706243	shares
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	203974000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	39968000	usd
	tlsi	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	203974000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	160507000	usd
	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	3499000	usd
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2871084	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9630000	usd
	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	25409000	usd
	tlsi	Reverse Recapitalization Stock Value If Converted Amount ReverseRecapitalizationStockValueIfConvertedAmount	220000000	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	-4171000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21097831	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13381126	shares
	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	2981000	usd
	tlsi	Income Loss From Preferred Stock Convertible Down Round Feature Per Basic Share IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare	-0.72
	tlsi	Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase Per Year Number Of Years ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1179480	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.66

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001826667-23-000007-index-headers.html	Edgar Link	pending
0001826667-23-000007-index.html	Edgar Link	pending
0001826667-23-000007.txt	Edgar Link	pending
0001826667-23-000007-xbrl.zip	Edgar Link	pending
ex311ceo302certification.htm	Edgar Link	pending
ex312cfo302certification.htm	Edgar Link	pending
ex321ceo906certification.htm	Edgar Link	pending
ex322cfo906certification.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlsi-20230930.htm	Edgar Link	pending
tlsi-20230930.xsd	Edgar Link	pending
tlsi-20230930_cal.xml	Edgar Link	unprocessable
tlsi-20230930_def.xml	Edgar Link	unprocessable
tlsi-20230930_pre.xml	Edgar Link	unprocessable
tlsi-20230930_lab.xml	Edgar Link	unprocessable
tlsi-20230930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TLSI
TriSalus Life Sciences Inc Stock $tlsi

2023 Q4 Form 10-Q Financial Statement

#000182666723000007 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLSI TriSalus Life Sciences Inc Stock $tlsi

2023 Q4 Form 10-Q Financial Statement

#000182666723000007 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLSI
TriSalus Life Sciences Inc Stock $tlsi